Coulter Partners secures industry-leading Chief Medical Officer for Solu Therapeutics
London, November 21, 2024 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, recently partnered with Solu Therapeutics (Solu) and is pleased to announce the placement of Sergio Santillana, MD, MSc, MBA, as Chief Medical Officer (CMO).
Solu Therapeutics is a biotechnology company pioneering novel therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas.